Shares of Nuformix plc (LON:NFX – Get Free Report) traded down 13% on Tuesday . The company traded as low as GBX 0.24 and last traded at GBX 0.24. 8,305,633 shares were traded during trading, a decline of 85% from the average session volume of 54,749,273 shares. The stock had previously closed at GBX 0.27.
Nuformix Price Performance
The stock has a 50 day simple moving average of GBX 0.30 and a 200-day simple moving average of GBX 0.17. The firm has a market cap of £4.96 million, a PE ratio of -0.60 and a beta of 1.22.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Featured Articles
- Five stocks we like better than Nuformix
- How to Invest in Small Cap Stocks
- 3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most
- How to Use Stock Screeners to Find Stocks
- Unassuming Evergy Energy: The AI Boost Your Income Portfolio Needs
- The Most Important Warren Buffett Stock for Investors: His Own
- Pfizer Adds to Its Big Bet on Weight Loss Drugs
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
